Tag: KDC-MN-302

  • SRT1720

    Selective SIRT1 activator

    An imidazothiazole SIRT1 activator; the structural lineage compound from which SRT2104 was developed.

    Abstract

    SRT1720 (CAS 925434-55-5; molecular formula C22H19N5OS2; molecular weight 433.55) is an imidazothiazole SIRT1 activator developed at Sirtris Pharmaceuticals as a potent (approximately 1000-fold over resveratrol) and selective sirtuin 1 activator. Mechanism is allosteric SIRT1 activation comparable to SRT2104. Mouse studies demonstrated lifespan extension in diet-induced obese mice, improved metabolic parameters, and reduced age-related pathology. The compound was the foundation for the broader Sirtris drug discovery program; SRT2104 was developed as a more drug-like successor with better human pharmacokinetics. SRT1720 is used preferentially in academic research where the established mouse pharmacology is valuable. Plasma half-life is approximately 8 to 10 hours.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.